SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 53 filers reported holding SPERO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $6 | -99.8% | 4 | -99.9% | 0.00% | – |
Q2 2022 | $3,000 | +200.0% | 4,120 | +3900.0% | 0.00% | – |
Q1 2022 | $1,000 | -99.2% | 103 | -98.8% | 0.00% | – |
Q1 2021 | $126,000 | -24.1% | 8,552 | 0.0% | 0.00% | – |
Q4 2020 | $166,000 | +38.3% | 8,552 | -20.5% | 0.00% | – |
Q3 2020 | $120,000 | -78.7% | 10,752 | -74.2% | 0.00% | – |
Q2 2020 | $564,000 | -29.5% | 41,652 | -57.9% | 0.00% | – |
Q1 2020 | $800,000 | -15.9% | 98,952 | 0.0% | 0.00% | – |
Q4 2019 | $951,000 | -47.4% | 98,952 | -42.0% | 0.00% | – |
Q3 2019 | $1,808,000 | -31.4% | 170,588 | -25.5% | 0.00% | – |
Q2 2019 | $2,635,000 | -47.2% | 228,952 | -41.2% | 0.00% | -100.0% |
Q1 2019 | $4,986,000 | +65.9% | 389,252 | -20.3% | 0.00% | – |
Q4 2018 | $3,005,000 | -53.7% | 488,552 | -21.0% | 0.00% | -100.0% |
Q3 2018 | $6,497,000 | -44.6% | 618,206 | -22.7% | 0.00% | 0.0% |
Q2 2018 | $11,736,000 | +2.9% | 800,000 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $11,400,000 | +21.3% | 800,000 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $9,400,000 | – | 800,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Atlas Venture Associates IX, LLC | 1,353,303 | $1,637,497 | 13.93% |
Anson Funds Management LP | 4,159,572 | $5,033,082 | 1.01% |
OUP Management Co., LLC | 249,070 | $301,375 | 0.68% |
Atlas Venture Life Science Advisors, LLC | 1,013,438 | $1,226,260 | 0.19% |
Murchinson Ltd. | 862,700 | $1,043,867 | 0.13% |
Alphabet Inc. | 889,979 | $1,076,874 | 0.07% |
AWM Investment Company, Inc. | 333,400 | $403,414 | 0.06% |
DAFNA Capital Management LLC | 125,000 | $151,250 | 0.05% |
Novo Holdings A/S | 468,902 | $567,371 | 0.04% |
XTX Topco Ltd | 58,368 | $70,625 | 0.01% |